Valsartan, a specific angiotensin II receptor blocker, inhibits pancreatic fluid secretion via vagal afferent pathway in conscious rats
| Autor: | Mitsuyoshi Yamamoto, Limin Wei, Masaru Harada, Makoto Otsuki, Munenori Otani |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Atropine
Male medicine.medical_specialty Angiotensin receptor Physiology Clinical Biochemistry Tetrazoles Muscarinic Antagonists Biochemistry Secretin Renin-Angiotensin System Cellular and Molecular Neuroscience Endocrinology Pancreatic Juice Internal medicine medicine Animals Rats Wistar Pancreas Cholecystokinin Pancreatic juice secretion Afferent Pathways Pancreatic Exocrine Secretion business.industry Proteins Vagus Nerve Valine Rats Bicarbonates medicine.anatomical_structure Valsartan Amylases Sensory System Agents Pancreatic juice Capsaicin business Angiotensin II Type 1 Receptor Blockers medicine.drug |
| Zdroj: | Regulatory Peptides. 178:80-85 |
| ISSN: | 0167-0115 |
| Popis: | Background/aim The renin–angiotensin system (RAS) exists in the pancreas, but the role of RAS in the regulation of pancreatic exocrine secretion under physiological conditions has been little known. The present study addressed the RAS's effect on the pancreatic secretion by using valsartan, a specific angiotensin II receptor blocker, in conscious rats. Method Male Wistar rats prepared with pancreatic, biliary, duodenal and jugular vein cannulas were used. To examine the role of RAS in the pancreatic secretion, valsartan at 1, 5, or 25 mg/kg was administered into the duodenum via cannula, and volume of pancreatic juice and protein concentration were determined. In addition, to examine the role of RAS in hormone-stimulated pancreatic hypersecretion, pancreatic secretion was examined in response to stimulation of secretin or cholecystokinin after intraduodenal infusion of valsartan at 25 mg/kg. Furthermore, to examine the mechanism of action of RAS on pancreatic secretion, intravenous infusion of atropine or perivagal application of capsaicin was conducted and then the pancreatic secretion was examined following intraduodenal infusion of valsartan at 25 mg/kg. Results Volume of pancreatic juice, but not protein output, significantly decreased after administration of valsartan. However, administration of valsartan did not exert significant effects on secretin- or cholesystokinin-stimulated pancreatic secretion. Treatment with atropine and perivagal application of capsaicin completely abolished the suppressive effect of valsartan on pancreatic juice secretion. Conclusion Present results suggest that RAS plays a stimulatory role in pancreatic juice secretion via cholinergic afferent pathway without affecting protein secretion and hormonally stimulated pancreatic secretion under physiological conditions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect